Biomarker

The FDA has granted breakthrough device designation to a phospho-tau 217 blood-based biomarker to assist in the diagnosis of Alzheimer’s disease, according to the manufacturer.

Two blood-based biomarkers may help identify patients with cancer who are more likely to experience gastrointestinal symptoms during chemotherapy.

Most oncologists treating non-small cell lung cancer reported more research into immunotherapy treatments, patients with comorbidities and biomarker testing will be vital to improving care, according to results of a nationwide survey.

In this edition, blood test for lung cancer patients who may benefit from further immunotherapy, invasive procedures following lung cancer screenings and more.

Next-generation technologies and diagnostic tests offer the promise of improved cancer care, but they also present challenges related to ensuring widespread access to these innovations.

In this video, Stephen M. Ansell, MD, PhD, discusses research presented at ASH Annual Meeting and Exposition on circulating tumor DNA.

Researchers reported that a universal risk prediction model incorporating traditional risk factors and cardiac biomarkers accurately estimated risk for adults both with and without baseline atherosclerotic CVD.

A biotechnology company has announced a partnership with a precision biomedicine firm to advance the use of electroencephalogram biomarkers across its clinical pipeline in neuropsychiatry and cognition.

The European Medicines Agency has approved enrollment for a phase 1/2a biomarker study to examine a once-daily, oral, brain penetrant mitochondrial stimulator to treat a range of neurological and neuromuscular conditions.

A clinical-stage biopharmaceutical company has reported new positive data from a 12-month long-term open label extension of the CNM-Au8 treatment arm in the HEALEY ALS Platform Trial.